
Published
22 September 2011 | By Kinapse
Phase II clinical development has traditionally been considered the ‘sweet spot’ for big pharma partnering deals. However our recent analysis reveals that discovery and early-stage clinical alliances are of increasing importance to big pharma’s long-term business strategy. This paper highlights the shifting industry trends responsible for the growth in earlier-stage partnering and describes how key stakeholders in the discovery space are evolving. We discuss the implications of this changing landscape for big pharma, and outline the new competences required to maximize value, mitigate risks and ultimately deliver new treatments to market.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory